Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,633,345
  • Shares Outstanding, K 64,765
  • Annual Sales, $ 78,590 K
  • Annual Income, $ -146,960 K
  • EBIT $ -200 M
  • EBITDA $ -202 M
  • 60-Month Beta 2.16
  • Price/Sales 32.25
  • Price/Cash Flow N/A
  • Price/Book 2.84

Options Overview Details

View History
  • Implied Volatility 67.17% ( +3.23%)
  • Historical Volatility 59.66%
  • IV Percentile 28%
  • IV Rank 31.46%
  • IV High 97.81% on 01/19/24
  • IV Low 53.10% on 11/27/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 1,614
  • Open Int (30-Day) 1,777

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.76
  • Number of Estimates 13
  • High Estimate -0.08
  • Low Estimate -1.01
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -204.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.09 +9.63%
on 12/19/24
49.35 -17.61%
on 12/02/24
-3.39 (-7.70%)
since 11/20/24
3-Month
37.09 +9.63%
on 12/19/24
53.27 -23.67%
on 09/26/24
-9.13 (-18.34%)
since 09/20/24
52-Week
22.35 +81.92%
on 01/04/24
53.27 -23.67%
on 09/26/24
+16.16 (+65.96%)
since 12/20/23

Most Recent Stories

More News
Insider Sale: Director at $KYMR (KYMR) Sells 2,500 Shares

Pamela Esposito, a director at $KYMR ($KYMR), sold 2,500 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares....

KYMR : 40.66 (+3.88%)
Kymera Therapeutics to Participate in Upcoming December Investor Conferences

KYMR : 40.66 (+3.88%)
Kymera Therapeutics to Participate in Upcoming November Investor Conferences

KYMR : 40.66 (+3.88%)
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

KYMR : 40.66 (+3.88%)
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

KYMR : 40.66 (+3.88%)
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

KYMR : 40.66 (+3.88%)
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

KYMR : 40.66 (+3.88%)
Stocks Undercut by Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.04%. US stocks Monday...

$SPX : 5,930.85 (+1.09%)
SPY : 591.15 (+1.20%)
$DOWI : 42,840.26 (+1.18%)
DIA : 428.54 (+1.24%)
$IUXX : 21,289.15 (+0.85%)
QQQ : 518.66 (+0.87%)
ZNH25 : 108-310s (+0.33%)
ARM : 132.15 (+0.04%)
MRO : 28.55 (-1.28%)
AMD : 119.21 (+0.28%)
MU : 90.12 (+3.48%)
LRCX : 71.79 (+0.81%)
Stocks Turn Lower as Chip Stocks Slide

The S&P 500 Index ($SPX ) (SPY ) is down -0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.08%. US stocks today are mixed, with the...

$SPX : 5,930.85 (+1.09%)
SPY : 591.15 (+1.20%)
$DOWI : 42,840.26 (+1.18%)
DIA : 428.54 (+1.24%)
$IUXX : 21,289.15 (+0.85%)
QQQ : 518.66 (+0.87%)
ZNH25 : 108-310s (+0.33%)
ARM : 132.15 (+0.04%)
MU : 90.12 (+3.48%)
NVDA : 134.70 (+3.08%)
MRO : 28.55 (-1.28%)
LRCX : 71.79 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 44.08
2nd Resistance Point 42.43
1st Resistance Point 41.54
Last Price 40.66
1st Support Level 39.01
2nd Support Level 37.36
3rd Support Level 36.47

See More

52-Week High 53.27
Fibonacci 61.8% 41.46
Last Price 40.66
Fibonacci 50% 37.81
Fibonacci 38.2% 34.16
52-Week Low 22.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar